AI assistant
MEMPHASYS LIMITED. — Share Issue/Capital Change 2011
Jul 26, 2011
65314_rns_2011-07-26_ba5cfca1-0b4d-4d56-a2b0-bfc58b3a372b.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
==> picture [196 x 25] intentionally omitted <==
==> picture [196 x 25] intentionally omitted <==
==> picture [196 x 25] intentionally omitted <==
==> picture [196 x 24] intentionally omitted <==
FOR IMMEDIATE RELEASE
NuSep 15¢ Bonus Share Option Issue
Sydney, Australia 27[th] July 2011 - NuSep (ASX: NSP) wishes to advise that it has applied to the ASX to have the 15¢ Bonus Share Options listed.
This issue of these share options is subject to NuSep shareholder approval. NuSep anticipates posting out a notice of meeting to shareholders in the next week.
The ASX has advised that subject to NuSep shareholder approval the share option code for the 15¢ Bonus Share Options will be NSPOA .
This will be a bonus pro rata issue of the 15¢ Share Options with an expiry date of 31[st] March 2012. For more details on these share options please refer to NuSep’s SPO prospectus dated 5 July 2011. The 15¢ Bonus Share Options will be issued on a pro rata 1 for 2 basis for all ordinary shares held on 12[th] September 2011.
ENDS
For more information please contact:
Contact: Prakash Patel Company Secretary +61 2 8415 7300 [email protected]
About NuSep
NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from Fraction to Function . The company has offices in both Sydney Australia and Atlanta, USA.
With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.
NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.
NuSep Products:
==> picture [12 x 17] intentionally omitted <==
Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.
NuSep Holdings Ltd 324 Burns Bay Rd Lane Cove NSW 2066
| minutes after use. | |||
|---|---|---|---|
| Postal Address | Contact Details | Email[email protected] | |
| P.O. Box 823 | Telephone | +61 2 8415 7300 | Webwww.nusep.com |
| Lane Cove NSW 1595 | Facsimile | +61 2 8415 7399 | ABN33 120 047 556 |
– 2 –
==> picture [12 x 17] intentionally omitted <==
Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF and is expected to undergoing clinical trials later this year.
==> picture [12 x 17] intentionally omitted <==
- Proteomics Software – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
==> picture [12 x 17] intentionally omitted <==
- Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.
For more information about NuSep please visit the company’s website www.NuSep.com
About SingaPharm
SingaPharm is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. SingaPharm is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). SingaPharm’s process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.
This process is flexible and modular compared with the large scale inflexible processing facilities of existing fractionators in US and Europe. The process has increased product yield relative to the existing process with increased product safety. The flexible nature of the PrIME technology also provides SingaPharm with access to plasma volumes that previously did not meet the criteria for larger scale processing facilities. Further, SingaPharm’s process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.